Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 19/20 | 0.74 |
| ▸ | HCAR3 | P49019 | 14/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099785 | 0.86 | HCAR2 (0.74) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3101235 | 0.85 | HCAR2 (1.00) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3103599 | 0.85 | HCAR2 (0.74) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL11293467 | 0.84 | HCAR2 (0.72) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3093524 | 0.84 | HCAR2 (0.77) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3094326 | 0.84 | HCAR2 (0.59) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3105600 | 0.81 | HCAR2 (0.57) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3092783 | 0.78 | HCAR2 (0.50) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL11293227 | 0.76 | HCAR2 (0.52) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL3101166 | 0.76 | HCAR2 (0.54) | HCAR2HCAR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161701-A1 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | claimed |
| JP-2007512346-A | — | — | 2007-05-17 | — | — | JP | claimed |
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | claimed |
| CN-1882557-A | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARM INC (US) | 2006-12-20 | — | — | CN | claimed |
| EP-1701947-A2 | 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2006-09-20 | — | — | EP | claimed |
| WO-2005051937-A2 | 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | WO | claimed |
| US-7803837-B2 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803837-B2 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803837-B2 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1701947-B1 | 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARM INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070161701-A1 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161701-A1 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161701-A1 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| CN-1882557-A | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARM INC (US) | 2006-12-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161701-A1 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ABAT, G6PD, GLS2 | HCAR2 229/4885HCAR3 373/4885CYP1A2 172/4885 |
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ABAT, G6PD, GLS2 | HCAR2 229/4885HCAR3 373/4885CYP1A2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.